{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stringent Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Progression free survival as defined by Partial Response (PR); Stable Disease (SD); Very Good Partial Response (VGPR), and Stringent Complete Response (sCR) to treatment. The outcome measures range from Stable disease to Stringent Complete Response (SD worst outcome; sCR best outcome","groups":[{"description":"CART-19 cells","id":"OG000","title":"Single Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Follow progression-free survival (PFS) for 2-3 years post CART-19 infusion","title":"Evaluate Progression Free Survival","type":"PRIMARY","unitOfMeasure":"participants"}